TARS vs TXT · rev $183.0M vs P/E 19, rev $13.70B
Tarsus Pharmaceuticals Inc (TARS) versus Textron Inc (TXT) — a side-by-side from cached financials, not a winner call.
Tarsus Pharmaceuticals Inc (TARS) is a biotechnology company listed on NASDAQ.
Textron Inc (TXT) is a aerospace & defense company listed on US.
Latest reported TARS revenue for 2024-12-31 was $183.0M. Net income was -$115.6M. Revenue was up 948.6% from 2023-12-31 to 2024-12-31. TARS currently screens at market cap $2.66B.
Latest reported TXT revenue for 2024-12-28 was $13.70B. Net income was $824.0M. Revenue was up 0.1% from 2023-12-30 to 2024-12-28. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
TARS currently screens at market cap $2.66B. TXT currently screens at market cap $14.85B and trailing P/E 18.5.
Not investment advice. Open the TARS and TXT stock pages for the full models.
Not investment advice.